Please login to the form below

Not currently logged in
Email:
Password:

finerenone

This page shows the latest finerenone news and features for those working in and with pharma, biotech and healthcare.

Bayer’s finerenone scores FDA priority review for chronic kidney disease

Bayer’s finerenone scores FDA priority review for chronic kidney disease

Finerenone – also known as BAY 94-8862 – is a selective mineralocorticoid receptor antagonist (MRA). ... On the primary endpoint of kidney failure outcomes, patients treated with finerenone an 18% relative risk reduction compared to the placebo group.

Latest news

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Bayer recently started three late-stage trials of its HF candidate finerenone - a mineralocorticoid drug designed as a safer replacement for older drugs in the class such as eplerenone and spironolactone,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
Serious about sustainability?
Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...